Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Dezzutti, Charlene S ^a   Hendrix, Craig W ^b   Marrazzo, Jeanne M ^c   Pan, Zhenyu ^e   Wang, Lei ^e   Louissaint, Nicolette ^b   Kalyoussef, Sabah ^f   Torres, N Merna ^f   Hladik, Florian ^d   Parikh, Urvi ^a   Mellors, John ^a   Hillier, Sharon L ^a   Herold, Betsy C ^f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 1; BETA DEFENSIN 2; DEFENSIN; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; GLUCONIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; NORMOSOL; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; WATER; ALPHA DEFENSIN; BIOLOGICAL MARKER; CYTOKINE; SLPI PROTEIN, HUMAN;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CERVICOVAGINAL LAVAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DACRON ENDOCERVICAL SWAB; DACRON VAGINAL SWAB; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLOCKED ENDOCERVICAL SWAB; FLOCKED VAGINAL SWAB; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MUCOSAL IMMUNITY; MUCUS SECRETION; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CYTOLOGY; VAGINAL LAVAGE; VAGINITIS; ANALYSIS OF VARIANCE; FEMALE GENITAL SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LABORATORY DIAGNOSIS; LAVAGE; METABOLISM; METHODOLOGY; MICROBIOLOGY; MUCOSA; RISK FACTOR; SOLUBILITY; UTERINE CERVIX; VAGINA; VAGINA SMEAR;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ALPHA-DEFENSINS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CERVIX UTERI; CYTOKINES; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-8; MUCOUS MEMBRANE; RISK FACTORS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SOLUBILITY; SPECIMEN HANDLING; THERAPEUTIC IRRIGATION; VAGINA; VAGINAL SMEARS; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 80051639401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023136     Document Type: Article

References (46)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
3. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
4. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977-1987.
5. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
6. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, et al. (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376: 1329-1337.
7. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957-966.
8. Hladik F, McElrath MJ, (2008) Setting the stage: host invasion by HIV. Nat Rev Immunol 8: 447-457.
9. Cummins JE Jr, Doncel GF, (2009) Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis 36: S84-91.
10. UNAIDS/WHO (2010) Report on global AIDS epidemic. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20101123_globalreport_en.pdf. Accessed 2011 Jul 27.
11. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L, (2005) Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 206: 306-335.
12. Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, et al. (2010) Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 63: 544-565.
13. Corey L, Wald A, Celum CL, Quinn TC, (2004) The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 35: 435-445.
14. McClelland RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, et al. (2007) Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 195: 698-702.
15. Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, et al. (2010) Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS ONE 5: e10094.
16. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
17. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5: e1000274.
18. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, et al. (2010) Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS ONE 5: e11366.
19. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, et al. (2007) PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 21: 467-476.
20. Shust GF, Cho S, Kim M, Madan RP, Guzman EM, et al. (2010) Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 63: 110-119.
21. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM, (2005) Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 175: 7560-7567.
22. Cummins JE, Christensen L, Lennox JL, Bush TJ, Wu Z, et al. (2006) Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 22: 788-795.
23. Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE, et al. (2011) Cervicovaginal Shedding of HIV Type 1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota. AIDS Res Hum Retroviruses 27: 35-39.
24. Jespers V, Harandi AM, Hinkula J, Medaglini D, Le Grand R, et al. (2010) Assessment of mucosal immunity to HIV-1. Expert Rev Vaccines 9: 381-394.
25. Lehrer RI, Ganz T, (2002) Defensins of vertebrate animals. Curr Opin Immunol 14: 96-102.
26. Belec L, Meillet D, Levy M, Georges A, Tevi-Benissan C, et al. (1995) Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays. Clin Diagn Lab Immunol 2: 57-61.
27. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS, (2008) Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 22: 1493-1501.
28. Ghanem KG, Johnson RE, Koumans EH, Marrazzo JM, Markowitz LE, (2005) Cervical specimen order and performance measures of Chlamydia trachomatis diagnostic testing. J Clin Microbiol 43: 5295-5297.
29. Ghanem KG, Koumans EH, Johnson RE, Sawyer MK, Papp JR, et al. (2006) Effect of specimen order on Chlamydia trachomatis and Neisseria gonorrhoeae test performance and adequacy of Papanicolaou smear. J Pediatr Adolesc Gynecol 19: 23-30.
30. Nugent RP, Krohn MA, Hillier SL, (1991) Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 29: 297-301.
31. Fichorova RN, Anderson DJ, (1999) Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 60: 508-514.
32. Wira CR, Grant-Tschudy KS, Crane-Godreau MA, (2005) Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am J Reprod Immunol 53: 65-76.
33. Chernesky M, Castriciano S, Jang D, Smieja M, (2006) Use of flocked swabs and a universal transport medium to enhance molecular detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 44: 1084-1086.
34. Krech T, Castriciano S, Jang D, Smieja M, Enders G, et al. (2009) Detection of high risk HPV and Chlamydia trachomatis in vaginal and cervical samples collected with flocked nylon and wrapped rayon dual swabs transported in dry tubes. J Virol Methods 162: 291-293.
35. Mitchell C, Paul K, Agnew K, Gaussman R, Coombs RW, et al. (2011) Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J Clin Microbiol 49: 735-736.
36. Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, et al. (2009) Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 83: 11196-11200.
37. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, et al. (2007) Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A 104: 1482-1487.
38. Berneman A, Belec L, Fischetti VA, Bouvet JP, (1998) The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infection & Immunity 66: 4163-4168.
39. Chomont N, Gresenguet G, Hocini H, Becquart P, Matta M, et al. (2001) Polymerase chain reaction for Y chromosome to detect semen in cervicovaginal fluid: a prerequisite to assess HIV-specific vaginal immunity and HIV genital shedding. AIDS 15: 801-802.
40. Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, et al. (2000) Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. American Journal of Obstetrics & Gynecology 183: 1243-1248.
41. Yudin MH, Landers DV, Meyn L, Hillier SL, (2003) Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 102: 527-534.
42. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, et al. (2007) Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 14: 1102-1107.
43. Valore EV, Wiley DJ, Ganz T, (2006) Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun 74: 5693-5702.
44. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, et al. (2011) A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel. PLoS One 6: e16475.
45. Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, et al. (2010) Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS ONE 5: e8781.
46. Alliance for Microbicide Development (2006) The Microbicide Development Strategy Silver Spring, MD Alliance for Microcide Development.